恒生医疗ETF（513060）高开，盘中持续震荡，截至发稿，上涨近1.5%，成交额近5亿元，换手率超 6%。成分股中半数上涨，亚盛医药-B、四环医药涨超8%；联邦制药、平安好医生、时代天使、再鼎医 药等个股跟涨，涨幅均超3%。 相关机构发文表示，当下的政策主线，政策+BD双轮驱动。目录双轨（基本医保+商保创新药）意味 着"能进医保走医保、谈不成进商保"的支付闭环雏形已定，释放"真创新更易放量"的信号；时间轴看， 8月公示收官→三季度评审与谈判→10–11月结果发布，政策催化将贯穿3–4个月窗口。对A+H公司而 言，已在公示名单内或具有新增适应症者，阶段性更易获得资金关注。 结构与节奏上，业绩线与事件线叠加。创新药在医保/商保支付"双轨"与MNC数百亿美元级BD"干火 药"共振下，中国创新药板块系统性重估仍在继续；互联网医疗（平台+药房/到家）在高增长与盈利改 善带动下，是H股医药里相对收益的主赛道之一；设备耗材侧，带量集采在部分品类节奏持续，短线对 单一产品依赖度高、议价能力弱的企业形成估值压制，但中长期关注出清后龙头份额提升与国产替代的 结构性机会。 上周港股冲高回落，恒指再度刷新阶段新高。港股三大指数今日 ...

近日，由上海交通大学医学院附属第九人民医院（以下简称"上海九院"）口腔正畸科团队与时代天 使合作研发的"数字化青少年小下颌畸形矫形器的研发及产业化"项目，凭借其创新性与卓越的产业化成 果，荣获"上海产学研合作优秀项目奖"一等奖。这一殊荣标志着项目在科研创新、学术推广和成果转化 方面取得了一个里程碑，也彰显了上海九院和时代天使在推动医疗健康产业高质量发展中踔厉前行、踏 实耕耘的精神风貌。 上海九院口腔正畸科房兵教授、时代天使CEO胡杰章 "上海产学研合作优秀项目奖"由上海市科委批准并经国家科技部备案，旨在表彰和鼓励产学研深度 合作、促进技术创新和成果转化。一等奖项目需在技术创新性、产业化成果和社会影响力等方面表现突 出。本次获奖的"数字化青少年小下颌畸形矫形器"项目，正是一次产学研结合、医工交叉的成功实践。 为了解决青少年小下颌畸形这一发病率高、对青少年咬合、容貌、心理健康有重要影响的牙颌面畸 形问题，上海九院与时代天使携手同行，集结了口腔临床医学研究人员、生物力学专家、工程师和产品 研发人员，充分发挥上海九院在口腔医学临床研究方面和时代天使在隐形矫治技术上的优势，深入分析 颌骨生长发育规律和现有器械的局限性， ...

Group 1 - The core issue is the continuous share reduction by the founder of Times Angel, Li Huamin, raising concerns about the company's future prospects [1] - Since its IPO, Li Huamin has reduced her shareholding from 14.26% to 6.37%, indicating a significant lack of confidence in the company's performance [1] - The company's market capitalization has plummeted approximately 88% from its peak of over 80 billion HKD to around 10 billion HKD [1] Group 2 - Times Angel has experienced a decline in net profit for three consecutive years, dropping from 286 million CNY in 2021 to only 10.02 million USD in 2024, indicating a systemic weakening of profitability [2] - The company's current price-to-earnings ratio stands at about 107 times, significantly higher than its competitor Align Technology's 34 times, suggesting that market expectations for future growth are not being met [2] - Despite substantial investments in overseas market expansion, Times Angel reported a loss of approximately 29.7 million USD in international markets for 2024, reflecting ongoing challenges in converting investments into profits [2] Group 3 - The global orthodontic industry is facing significant challenges, as evidenced by Align Technology's stock price drop of 30% due to poor Q2 performance and layoffs, indicating potential market saturation [2] - Times Angel's overseas revenue remains minimal, with high investment costs and long conversion cycles, posing risks amid intense international competition [2] - Industry experts suggest that without a rapid increase in sales to support its valuation, Times Angel may face escalating challenges in the near future [2]

格隆汇8月7日丨时代天使(06699.HK)公告，公司将于2025年8月25日举行董事会会议，藉以（其中包 括）考虑及批准集团截至2025年6月30日止六个月的未经审计中期业绩及其刊发，考虑派发中期股息 （如有），以及处理其他事项。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 ANGELALIGN TECHNOLOGY INC. 時代天使科技有限公司 （於開曼群島註冊成立的有限公司） （股份代號：6699） 董事會召開日期 時代天使科技有限公司（「本公司」，連同其附屬公司統稱「本集團」）董事會（「董 事會」）謹此宣佈，本公司將於2025年8月25日（星期一）舉行董事會會議，藉以 （其中包括）考慮及批准本集團截至2025年6月30日止六個月之未經審計中期業績 及其刊發，考慮派發中期股息（如有），以及處理其他事項。 承董事會命 時代天使科技有限公司 主席 馮岱先生 香港，2025年8月7日 於本公告日期，董事會包括執行董事胡杰章先生、黃琨先生、宋鑫先生及董莉女 士；非執行董事馮岱先生；獨立非執行董事韓小京先生、石子先生及周浩先生。 ...

相关企业：爱齐（上海）商贸有限公司、成都新桥口腔医院有限公司、正雅齿科科技（上海）有限公 司、西安市恒惠科技有限公司、北京美立刻医疗器械有限公司、可丽尔医疗科技（常州）有限公司、天 津正丽科技有限公司、广州瑞通生物科技有限公司等。 关键词：牙齿矫治器分类、隐形矫治器的分类、隐形矫治器行业发展历程、居民人均医疗保健支出、隐 形矫治器行业产业链、正畸案例数、隐形正畸案例数、正畸市场规模、隐形正畸市场规模、隐形矫治器 行业市场规模、隐形矫治器行业发展趋势 一、隐形矫治器行业概述 内容概况：隐形矫治技术作为现代正畸领域的重大突破，在传承传统牙颌畸形矫治理念的基础上实现了 革命性创新，通过采用安全透明的弹性高分子材料制成的隐形矫治器，完全摒弃了传统托槽和钢丝的束 缚，让牙齿矫正过程既高效又隐蔽，且不影响日常生活和社交。近年来，随着人们对口腔健康和美观需 求的日益增强，隐形矫治器凭借其舒适、美观、便捷的特点，逐渐成为牙齿矫正市场的重要选择。尤其 是年轻一代消费者，更倾向于选择兼具功能性和美观性的隐形矫治方案，推动行业市场规模不断扩大。 与此同时，技术进步和产业链的完善进一步降低了隐形矫治器的生产成本，使得更多消费者能够负 ...

Group 1: Financial Performance - The company expects to achieve a net profit of $13.4 to $14.8 million in H1 2025, representing a year-on-year growth of 538.1% to 604.8% [1] - The growth in net profit is primarily driven by a low base in H1 2024, continued growth in overseas markets, and lower investment and operating expenses due to delays in establishing overseas production facilities [1] - Revenue projections for 2025 to 2027 are estimated at $318 million, $374 million, and $445 million, with year-on-year growth rates of 18.1%, 17.8%, and 18.8% respectively [3] Group 2: Market Expansion and Strategy - The company has made a strategic investment in the invisible orthodontics brand Shuyaki, acquiring a 35% stake to deepen its presence in emerging markets [2] - The company is focusing on enhancing accessibility to orthodontic services in lower-tier cities and county markets through its investment in Shuyaki, which is recognized for its cost-effective products and digital services [2] - The company has established a highly specialized team in Europe, Asia-Pacific, and the Americas, accelerating its overseas business with a significant increase in international cases from 33,000 in 2023 to 140,700 in 2024, a growth of 326.4% [1] Group 3: Marketing and Brand Influence - The company is expanding its sales and clinical teams strategically based on the development characteristics of different city tiers and is employing diversified marketing strategies to enhance brand influence [3] - Collaborative marketing initiatives include a summer event with Hasbro's My Little Pony in Shanghai, aimed at promoting early orthodontic education and family interaction [3] - The company launched the "Angel KiD Star Plan" in partnership with Xiaohongshu to promote early orthodontic awareness through authoritative reports and expert collaboration [3]

智通财经APP获悉，港股三大指数今日涨跌不一，恒指盘中重回两万五关后回落，截止收盘，恒生指数 涨0.03%或8.1点，报24910.63点，全日成交额为2152.35亿港元；恒生国企指数跌0.21%，报8932.68点； 恒生科技指数涨0.2%，报5532.17点。 浙商国际指出，港股市场基本面仍偏弱，资金面环境内外部分化，政策面后续或仅"托而不举"，情绪面 短期预计仍偏观望。鉴于市场中长期趋势已进入右侧区间，对于后续走势，该行不建议过度悲观。对于 中短期市场走势继续保持谨慎乐观的态度。 蓝筹股表现 比亚迪电子(00285)领涨蓝筹。截至收盘，涨6.72%，报37.8港元，成交额34亿港元，贡献恒指3.01点。 近期海外CSP大厂及相关液冷供应商发布25年二季度业绩及全年指引，业绩均超市场预期、Capex继续 上调。公开资料显示，公司产品线涵盖企业级通用服务器、存储服务器、AI服务器及液冷散热方案 等，公司及子公司为英伟达合作伙伴，与英伟达合作进行液冷研发。 其他蓝筹股方面，中芯国际(00981)涨3.14%，报52.6港元，贡献恒指11.33点；中国神华(01088 )涨 2.99%，报36.54港元，贡献 ...

Core Viewpoint - UBS reports that Times Angel (06699) is expected to achieve a net profit of $13.4 million to $14.8 million in the first half of the year, representing a year-on-year growth of 538% to 605%, exceeding market expectations [1] Financial Performance - The significant growth in both local and overseas revenue is anticipated to positively influence investor sentiment [1] - UBS has raised its earnings per share (EPS) forecast for Times Angel by 105% to HKD 1.18, reflecting lower-than-expected operating expenses [1] - Assuming overseas operations reach breakeven by 2027, the EPS forecast for 2027 has been increased by 7% to HKD 2.02 [1] Investment Recommendation - UBS sets a target price of HKD 82 for the stock and reiterates a "Buy" rating [1]

Core Viewpoint - UBS reports that Times Angel (06699) is expected to achieve a net profit of between 13.4 million to 14.8 million USD in the first half of the year, representing a year-on-year growth of 538% to 605%, exceeding market expectations [1] Financial Performance - The significant growth in both local and overseas revenue is anticipated to positively influence investor sentiment [1] - UBS has raised its earnings per share (EPS) forecast for Times Angel by 105% to 1.18 HKD, reflecting lower-than-expected operating expenses [1] - Assuming that overseas business reaches breakeven by 2027, the EPS forecast for 2027 has been increased by 7% to 2.02 HKD [1] Investment Recommendation - UBS sets a target price of 82 HKD for the stock and reiterates a "Buy" rating [1]